#### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

#### ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

October 14, 2005

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* **ENDO PHARMA LLC** 

(First)

(Street)

(Middle)

5. Relationship of Reporting Person(s) to Issuer

Symbol

(Check all applicable)

Officer (give title

**ENDO PHARMACEUTICALS** HOLDINGS INC [ENDP]

2. Issuer Name and Ticker or Trading

Director

\_X\_\_ 10% Owner

\_ Other (specify

320 PARK AVENUE

3. Date of Earliest Transaction

(Month/Day/Year) 10/12/2005

below)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

NEW YORK, NY 10022

(City)	(State)	(Zip) Tal	ble I - Non	-Derivative Sec	urities	S Acquire	d, Disposed of, o	r Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	(A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$.01 per share	10/12/2005		Code V	Amount 21,261,905	(D)	Price \$ 26.04		D	
Common Stock, par value \$.01 per share	10/12/2005		X	1,892,838	D	\$ 3	40,029,541	D	
Common Stock, par	10/12/2005		X	888,000	D	\$ 3.42	39,141,541	D	

## Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

value \$.01 per share							
Common Stock, par value \$.01 per share	10/12/2005	X	5,114,279	D	\$ 2.42	34,027,262	D
Common Stock, par value \$.01 per share	10/12/2005	X	688,526	D	\$ 3	33,338,736	D
Common Stock, par value \$.01 per share	10/12/2005	X	254,323	D	\$ 2.42	33,084,413	D
Common Stock, par value \$.01 per share	10/12/2005	X	1,435,826	D	\$ 3	31,648,587	D
Common Stock, par value \$.01 per share	10/12/2005	X	2,581,137	D	\$ 2.42	29,067,450	D
Common Stock, par value \$.01 per share	10/12/2005	X	3,016,029	D	\$ 3	26,051,421	D
Common Stock, par value \$.01 per share	10/12/2005	X	2,225,273	D	\$ 2.42	23,826,148	D
Common Stock, par value \$.01 per share	10/12/2005	X	1,400,356	D	\$ 3	22,425,792	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474 (9-02)

#### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Securi (Instr. 3 and 4)	
				Code V (A)	(D)	Date Exercisable	Expiration Date	Title	Amo Nun Shar
Call Option (obligation to sell)	\$ 3	10/12/2005		X	1,892,838	10/12/2005	08/26/2007	Common Stock	1,8
Call Option (obligation to sell)	\$ 3.42	10/12/2005		X	888,000	10/12/2005	08/26/2007	Common Stock	88
Call Option (obligation to sell)	\$ 2.42	10/12/2005		X	5,114,279	10/12/2005	08/26/2007	Common Stock	5,1
Call Option (obligation to sell)	\$ 3	10/12/2005		X	688,526	10/12/2005	08/26/2007	Common Stock	68
Call Option (obligation to sell)	\$ 2.42	10/12/2005		X	254,323	10/12/2005	08/26/2007	Common Stock	25
Call Option (obligation to sell)	\$ 3	10/12/2005		X	1,435,826	10/12/2005	08/26/2007	Common Stock	1,4
Call Option (obligation to sell)	\$ 2.42	10/12/2005		X	2,581,137	10/12/2005	08/26/2007	Common Stock	2,5
Call Option (obligation to sell)	\$ 3	10/12/2005		X	3,016,029	10/12/2005	08/26/2007	Common Stock	3,0
Call Option (obligation to sell)	\$ 2.42	10/12/2005		X	2,225,273	10/12/2005	08/26/2007	Common Stock	2,2
Call Option (obligation to sell)	\$ 3	10/12/2005		X	1,400,356	10/12/2005	08/26/2007	Common Stock	1,4

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

X

ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022

**Signatures** 

/s/ Jeffrey R. Black Chief Financial
Officer 10/14/2005

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 4